Strona główna・Stock List・Johnson and Johnson

Johnson and Johnson

Closed

SectorHealthcare

259.5 -0.87

Buy Sell

Overview

Share price change

24h

Current

Min

258.5

Max

261.83

Key metrics
By Trading Economics
Income	299M 5.5B
Sales	1.2B 25B
P/E Sector Avg	29.548 68.51
EPS	2.9
Dividend yield	2.04
Profit margin	21.865
Employees	138,200
EBITDA	-1.1B 7.2B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+7.33% upside

Dividends
By Acuity
Dividend yield Sector Avg	2.04% 2.29%
Next Earnings	13 paź 2026
Next Dividend date	8 wrz 2026
Next Ex Dividend date	25 sie 2026

Market Stats
By TradingEconomics
Market Cap	-5.5B 613B
Previous open	260.37
Previous close	259.5

News Sentiment

By Acuity

23%

77%

41 / 340 Ranking in Healthcare

Johnson and Johnson Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 sie 2026, 23:06 UTC

News

Johnson & Johnson will present at the Morgan Stanley Healthcare Conference on September 14, 2026. Shares are roughly flat in after-market trading.

8 sie 2026, 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

7 sie 2026, 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

6 sie 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

5 sie 2026, 23:51 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

4 sie 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

3 sie 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

1 sie 2026, 00:01 UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

31 lip 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

30 lip 2026, 18:22 UTC

News

Event

Johnson & Johnson shares are lower amid concerns over a $1 billion acquisition of Firefly Bio and a partnership with Sail Biomedicines, impacting future earnings.

29 lip 2026, 21:41 UTC

News

Johnson & Johnson lowered its fiscal year 2026 adjusted EPS guidance to $10.86 to $11.01, contributing to a decline in after-market trading.

28 lip 2026, 23:31 UTC

Johnson & Johnson shares are higher in after-market trading, remaining above their 20-day moving average after six consecutive daily gains.

27 lip 2026, 23:31 UTC

News

Social Media

Johnson & Johnson shares are higher in after-market trading following a proposed $5.5 billion settlement for ovarian talc litigation involving about 76,000 claims.

24 lip 2026, 23:26 UTC

Johnson & Johnson shares declined in after-market trading, continuing a downward trend since Friday's close, despite the broader market's stability amid bond market concerns.

23 lip 2026, 10:06 UTC

Event

Johnson & Johnson's OTTAVA™ Robotic Surgical System received FDA authorization. Shares are lower in pre-market trading amid broader market declines.

22 lip 2026, 23:36 UTC

Event

Johnson & Johnson shares are higher in after-market trading following FDA authorization of the OTTAVA™ Robotic Surgical System, the first table-integrated soft tissue robotic system.

21 lip 2026, 23:11 UTC

Shares of Johnson & Johnson are higher in after-market trading, with no specific news identified. The stock remains below its 20-day moving average.

20 lip 2026, 19:26 UTC

Social Media

News

Johnson & Johnson shares are lower today, continuing a decline since Friday. The company targets $101 billion in revenue amid bearish technical trends.

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

7.33% upside

12 Months Forecast

Average 281 USD 7.33%

High 305 USD

Low 255 USD

Based on 17 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Based on 17 analysts giving stock ratings to Johnson and Johnson - Dist in the past 3 months.

Sentiment

By Acuity

41 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.